 multidrug-resist myeloma laboratori clinic effect verapamil chemosensit verapamil chemosensit multidrug resist multipl myeloma vitro clinic trial bone myeloma patient relaps sever resist paramet express p-glycoprotein adriamycin vincristin sensit abil ad verapamil resist cytotox agent verapamil capabl myeloma cell resist vitro sensit cell drug sensit myeloma cell doxorubicin resist vitro cell clinic trial patient myeloma refractori vincristine-adriamycin-dexamethason vad vad high-dos intraven verapamil Ve patient vad/v partial remiss median relapse-fre surviv vad/v respond month overal surviv start vad/v nonrespond subset patient myeloma cell posit wherea none patient myeloma cell remiss vad/v myeloma cell vad/v clinic respond vitro chemosensit verapamil wherea vitro verapamil chemosensit clinic nonrespond observ clinic revers multidrug resist patient vad-refractori myeloma use verapamil addit valu drug develop vitro test express chemosensit cytotox drug patient bone marrow myeloma cell patient chemosensitizer-contain regimen chemosensit capabl multidrug resist role treatment hematolog malign b-cell neoplasm multipl myeloma non-hodgkin lymphoma